Format

Send to

Choose Destination
Anticancer Drugs. 2017 Oct;28(9):1053-1055. doi: 10.1097/CAD.0000000000000536.

Clinical activity of eribulin in advanced desmoplastic small round-cell tumor.

Author information

1
Departments of aMedical Oncology bRadiology cPathology dSurgery, Institut Bergonie, Bordeaux, France.

Abstract

Desmoplastic small round-cell tumor is a rare but highly aggressive tumor occurring mainly in adolescents and young adults. Prolonged progression-free survival has been documented in patients who have undergone aggressive multimodality therapy - that is, multiagent intensive chemotherapy, debulking surgery, and radiation therapy. Eribulin is a microtubule-dynamics inhibitor, and it has recently been shown to be active in liposarcomas. In preclinical models, eribulin activities have also been shown to occur in Ewing's sarcoma cell lines, rhabdomyosarcomas and osteosarcomas. In this study, we report three cases of male patients suffering from desmoplastic small round-cell tumor and the clinical response to eribulin in two of them.

PMID:
28863036
DOI:
10.1097/CAD.0000000000000536
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center